Prevalence of benzodiazepine use disorder during hospitalization for alcohol detoxification
Abstract Benzodiazepines (BZDs) are the first‐line treatment of alcohol withdrawal. Comorbidity between benzodiazepine use disorder (BUD) and alcohol use disorders (AUD) is common. However, the risk factors are poorly characterized due to the paucity of available BUD screening tools. The present study aimed to rectify this by conducting an observational screening investigation for BUD in patients hospitalized for alcohol detoxification in a specialized unit. During a face‐to‐face interview, a short BUD screening tool, Echelle Cognitive d'Attachement aux benzodiazépines(ECAB), was administered to record recent patterns of BZD use, thereby allowing categorization of AUD patients as follows: non‐BZD users, BZD users without BUD, and BUD (ECAB ≥6). Clinical and sociodemographic risk factors were identified and recorded during clinical assessment and were analyzed using nonparametric bivariate tests and multinomial regression for association with BUD, with p < 0.05 for significance. Of the 150 AUD patients, 23 (15%) had comorbid BUD. Several variables were associated with ECAB score, with their independence being verified using multinomial regression, with lower risk of BUD versus BZD use, when the initial prescriber was an addiction specialist compared with a psychiatrist or a general practitioner [odds ratio (OR) = 0.12, 95% confidence interval (CI) = 0.14–0.75]. A higher risk of BZD use versus no use was evident when comorbid psychiatric disorders were present (OR = 9.2, 95%CI = 1.3–65). Our findings raise clinicians' awareness that in patients hospitalized for alcohol detoxification, BUD is highly prevalent but not specifically related to psychiatric disorders. BUD can be effectively screened by utilization of the ECAB..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:37 |
|---|---|
| Enthalten in: |
Fundamental & Clinical Pharmacology - 37(2023), 4, Seite 849-857 |
| Beteiligte Personen: |
Crosnier Leconte, Gilles [VerfasserIn] |
|---|
| Anmerkungen: |
© 2023 John Wiley & Sons, Ltd. |
|---|
| Umfang: |
9 |
|---|
| doi: |
10.1111/fcp.12888 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
WLY015680797 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | WLY015680797 | ||
| 003 | DE-627 | ||
| 005 | 20231111155635.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231111s2023 xx |||||o 00| ||und c | ||
| 024 | 7 | |a 10.1111/fcp.12888 |2 doi | |
| 028 | 5 | 2 | |a 2023-11-11_FCP_2023_37_4.zip.xml |
| 035 | |a (DE-627)WLY015680797 | ||
| 035 | |a (WILEY)FCP12888 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 100 | 1 | |a Crosnier Leconte, Gilles |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Prevalence of benzodiazepine use disorder during hospitalization for alcohol detoxification |
| 264 | 1 | |c 2023 | |
| 300 | |a 9 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a © 2023 John Wiley & Sons, Ltd. | ||
| 520 | |a Abstract Benzodiazepines (BZDs) are the first‐line treatment of alcohol withdrawal. Comorbidity between benzodiazepine use disorder (BUD) and alcohol use disorders (AUD) is common. However, the risk factors are poorly characterized due to the paucity of available BUD screening tools. The present study aimed to rectify this by conducting an observational screening investigation for BUD in patients hospitalized for alcohol detoxification in a specialized unit. During a face‐to‐face interview, a short BUD screening tool, Echelle Cognitive d'Attachement aux benzodiazépines(ECAB), was administered to record recent patterns of BZD use, thereby allowing categorization of AUD patients as follows: non‐BZD users, BZD users without BUD, and BUD (ECAB ≥6). Clinical and sociodemographic risk factors were identified and recorded during clinical assessment and were analyzed using nonparametric bivariate tests and multinomial regression for association with BUD, with p < 0.05 for significance. Of the 150 AUD patients, 23 (15%) had comorbid BUD. Several variables were associated with ECAB score, with their independence being verified using multinomial regression, with lower risk of BUD versus BZD use, when the initial prescriber was an addiction specialist compared with a psychiatrist or a general practitioner [odds ratio (OR) = 0.12, 95% confidence interval (CI) = 0.14–0.75]. A higher risk of BZD use versus no use was evident when comorbid psychiatric disorders were present (OR = 9.2, 95%CI = 1.3–65). Our findings raise clinicians' awareness that in patients hospitalized for alcohol detoxification, BUD is highly prevalent but not specifically related to psychiatric disorders. BUD can be effectively screened by utilization of the ECAB. | ||
| 700 | 1 | |a Clergue‐Duval, Virgile |4 aut | |
| 700 | 1 | |a Bloch, Vanessa |4 aut | |
| 700 | 1 | |a Barre, Thomas |4 aut | |
| 700 | 1 | |a Amami, Jihed |4 aut | |
| 700 | 1 | |a Bellivier, Frank |4 aut | |
| 700 | 1 | |a Questel, Frank |4 aut | |
| 700 | 1 | |a Vorspan, Florence |4 aut | |
| 700 | 1 | |a Icick, Romain |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Fundamental & Clinical Pharmacology |g 37(2023), 4, Seite 849-857 |w (DE-627)WLY005640377 |x 14728206 |7 nnns |
| 773 | 1 | 8 | |g volume:37 |g year:2023 |g number:4 |g pages:849-857 |g extent:9 |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_WLY | ||
| 951 | |a AR | ||
| 952 | |d 37 |j 2023 |e 4 |h 849-857 |g 9 | ||